Phase 4 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer confirmed by a laboratory test on tissue or cell samples.
- People who are 18 years of age or older.
- People who are already planned to receive a standard treatment called 177Lu-Vipivotide Tetraxetan following a specific type of scan (18F-DCFPyL PSMA-PET).
- People who have had a specific type of scan (68Ga-PSMA-11 PSMA-PET) within the last 120 days showing at least one area of concern detected by that scan, as required to be eligible for the 177Lu-Vipivotide Tetraxetan treatment.
- People who are able and willing to follow all study procedures.
- People who have had or currently have another type of cancer, as long as that cancer or its treatment is unlikely to affect the safety or results of this study (confirm with trial site).
- Women who could become pregnant, and men, must agree to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) before joining the study and for 24 hours after the study scan, due to unknown effects of the scan agent on an unborn baby.
- People who are able to understand the study and are willing to sign a written consent form.
Who may not be able to join:
- People with serious uncontrolled illnesses, such as an active infection, severe heart failure, unstable chest pain, or an irregular heartbeat.
- People who have reasons they cannot have a PET/CT scan, including severe claustrophobia (fear of enclosed spaces).
- People who have previously had an allergic reaction to a drug or substance with a similar make-up to the scan agent used in this study (18F-DCFPyL).
- People who have any past or current health condition that, in the opinion of the study investigators, could affect the study results or create additional risk by taking part.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Heather Jacene, MD, Dana-Farber Cancer Institute
Phone: 617-632-3767
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of Participants with PSMA-Positive Lesion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.